ワクチンアジュバントの市場：製品、投与経路、疾患、用途別-2025年～2030年の世界予測

ワクチンアジュバント市場は、2023年に8億2,565万米ドルと評価され、2024年には8億8,418万米ドルに達すると予測され、CAGR 7.88%で成長し、2030年には14億420万米ドルに達すると予測されています。

ワクチンアジュバントは、免疫反応を調節することによってワクチンの有効性を高めるために使用される重要な成分です。アジュバントの必要性は、抗原に対する免疫反応を増強し、必要な抗原量を減少させ、ワクチンの安定性を向上させる能力にあり、特にHIV、マラリア、がんなどの課題疾患に対する新しいワクチンの開発に不可欠なものとなっています。特にHIV、マラリア、がんなどの難病を対象とした新しいワクチンの開発には欠かせないものとなっています。これらのワクチンは主に、感染症の予防ワクチンや、慢性疾患やがんを対象とした治療ワクチンに応用されています。主な最終用途分野には、製薬会社、学術研究機関、バイオテクノロジー企業などがあります。市場開拓は、感染症や慢性疾患の流行増加、予防接種プログラムへの注目の高まり、アジュバント製剤の進歩、ワクチン開発に対する政府の支援政策などの影響を受けています。新規デリバリーシステムや次世代アジュバント製剤など、最近の技術革新は成長の機会をもたらしています。これらを活用するため、利害関係者は、特に予防接種ニーズが満たされていない新興市場において、戦略的パートナーシップや研究開発投資の拡大に注力すべきです。しかしながら、ワクチン承認に関する厳しい規制ガイドライン、免疫原性の懸念、アジュバントに関連する潜在的副作用などの課題に直面しており、これらは採用率の妨げとなる可能性があります。研究・生産コストが高いことも、多くの企業にとって制約となります。技術革新の余地がある分野としては、より広範な免疫応答を誘導できるアジュバント、小児用アジュバント、パンデミック対策用アジュバントなどの開発があり、これらは市場に大きな優位性をもたらす可能性があります。市場は競争が激しく、研究主導の成長戦略が重視されています。全体として、安全性と有効性を確保するアジュバント技術の進歩と、より円滑な承認を促進する規制戦略が、市場シェアを獲得するために不可欠となります。政府機関および非政府組織の両方と提携を結び、技術革新の先陣を切り続ける企業は、進化するワクチン開発の状況において成功するための最良のポジションにつくと思われます。

市場力学：急速に進化するワクチンアジュバント市場の主要市場インサイトを公開

ワクチンアジュバント市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症および人獣共通感染症の増加
  • ワクチンの有効性を高める必要性
  • 畜産業の成長と関連疾患の流行
• 市場抑制要因
  • ミネラルアジュバントと組換えタンパク質およびサブユニットワクチンの不適合
• 市場機会
  • コンビネーションアジュバントの可能性の高まり
  • ワクチン開発の増加
• 市場の課題
  • 資本集約的で時間のかかる開発と承認プロセス

ポーターのファイブフォースワクチンアジュバント市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ワクチンアジュバント市場における外部からの影響の把握

外部マクロ環境要因は、ワクチンアジュバント市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ワクチンアジュバント市場における競合情勢の把握

ワクチンアジュバント市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスワクチンアジュバント市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ワクチンアジュバント市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ワクチンアジュバント市場における成功への道筋を描く

ワクチンアジュバント市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症および人獣共通感染症の発生率の増加
    • ワクチンの有効性を高める必要性
    • 畜産事業の拡大とそれに伴う疾病の蔓延
  • 抑制要因
    • ミネラルアジュバントと組み換えタンパク質およびサブユニットワクチンとの不適合性
  • 機会
    • 複合アジュバントの潜在能力の高まり
    • ワクチン開発の拡大
  • 課題
    • 資本集約的で時間のかかる開発および承認プロセス
• 市場セグメンテーション分析
  • 疾患：がんワクチンの有効性を高めるためのワクチンアジュバントの使用が急増
  • 製品：免疫力が低下した人向けのアジュバント乳剤の好感度が高まっている
  • 応用：ヒトワクチンにおけるワクチンアジュバントの使用増加
  • 投与経路：皮内投与によるワクチンアジュバントの使用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ワクチンアジュバントの市場：製品別

• アジュバントエマルジョン
• 複合アジュバント
• ミネラルアジュバント
• 微粒子アジュバント

第7章 ワクチンアジュバントの市場：投与経路別

• 皮内
• 筋肉内
• 鼻腔内
• 経口
• 皮下

第8章 ワクチンアジュバントの市場：疾患別

• がん
• 感染症

第9章 ワクチンアジュバントの市場：用途別

• 人間
• 獣医

第10章 南北アメリカのワクチンアジュバントの市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋のワクチンアジュバントの市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのワクチンアジュバントの市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • プリツカー分子工学大学院が次世代ワクチンの開発に向け産学連携を開始
  • Croda Partnersのワクチンアジュバント
  • オックスフォード大学が開発したR21/マトリックスMマラリアワクチンがガーナでの使用許可を取得
• 戦略分析と提言

企業一覧

• Agenus Inc.
• Aphios Corporation
• Bioveta, A.S.
• Croda International PLC
• CSL Limited
• Dynavax Technologies Corporation
• GlaxoSmithKline PLC
• Hayashibara Co., Ltd. by NAGASE & CO., LTD.
• InvivoGen
• Merck KGaA
• Novavax, Inc.
• OZ Biosciences SAS
• Pacific GeneTech Limited
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
• FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VACCINE ADJUVANTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VACCINE ADJUVANTS MARKET DYNAMICS
• TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 193. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023

The Vaccine Adjuvants Market was valued at USD 825.65 million in 2023, expected to reach USD 884.18 million in 2024, and is projected to grow at a CAGR of 7.88%, to USD 1,404.20 million by 2030.

Vaccine adjuvants are critical components used to enhance the efficacy of vaccines by modulating the immune response. The necessity of adjuvants lies in their ability to enhance immune reactions to antigens, reduce the amount of antigen required, and improve vaccine stability, making them indispensable in developing new vaccines, especially for challenging diseases like HIV, malaria, and cancer. They are predominantly applied in prophylactic vaccines for infectious diseases and therapeutic vaccines targeting chronic diseases and cancers. Key end-use sectors include pharmaceutical companies, academic research institutions, and biotechnology firms. Market growth is influenced by the rising prevalence of infectious and chronic diseases, increasing focus on immunization programs, advancements in adjuvant formulations, and supportive government policies for vaccine development. Recent technological innovations, such as novel delivery systems and next-generation adjuvant formulations, present opportunities for growth. To capitalize on these, stakeholders should focus on strategic partnerships and increased R&D investments, especially in emerging markets with unmet immunization needs. However, the market faces challenges such as stringent regulatory guidelines for vaccine approval, immunogenicity concerns, and potential side effects associated with adjuvants, which can hinder adoption rates. The high cost of research and production can also pose a limitation for many firms. Areas ripe for innovation include the development of adjuvants that can induce broader immune responses, pediatric-specific adjuvants, and adjuvants for use in pandemic preparedness, which could offer significant market advantages. The market is highly competitive, with a strong emphasis on research-driven growth strategies. Overall, advancing adjuvant technologies that ensure safety and efficacy, along with regulatory strategies that facilitate smoother approvals, will be vital for capturing market share. Firms that stay ahead in innovation, forming alliances with both governmental and non-governmental organizations, will be best positioned for success in the evolving landscape of vaccine development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Adjuvants Market

The Vaccine Adjuvants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of infectious and zoonotic diseases
  • Need to increase the effectiveness of vaccines
  • Growth in livestock operations and prevalence of associated diseases
• Market Restraints
  • Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
• Market Opportunities
  • Rising potential of combination adjuvants
  • Increasing development of vaccines
• Market Challenges
  • Capital-intensive and time-consuming development and approval process

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Adjuvants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Adjuvants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Adjuvants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Adjuvants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Adjuvants Market

A detailed market share analysis in the Vaccine Adjuvants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Adjuvants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Adjuvants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Adjuvants Market

A strategic analysis of the Vaccine Adjuvants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants, and Particulate Adjuvants.
• Based on Route of Administration, market is studied across Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous.
• Based on Disease, market is studied across Cancer and Infectious Diseases.
• Based on Application, market is studied across Human and Veterinary.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of infectious and zoonotic diseases
    • 5.1.1.2. Need to increase the effectiveness of vaccines
    • 5.1.1.3. Growth in livestock operations and prevalence of associated diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising potential of combination adjuvants
    • 5.1.3.2. Increasing development of vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Capital-intensive and time-consuming development and approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
  • 5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
  • 5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
  • 5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Vaccine Adjuvants Market, by Product

• 6.1. Introduction
• 6.2. Adjuvant Emulsions
• 6.3. Combination Adjuvants
• 6.4. Mineral Adjuvants
• 6.5. Particulate Adjuvants

7. Vaccine Adjuvants Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intradermal
• 7.3. Intramuscular
• 7.4. Intranasal
• 7.5. Oral
• 7.6. Subcutaneous

8. Vaccine Adjuvants Market, by Disease

• 8.1. Introduction
• 8.2. Cancer
• 8.3. Infectious Diseases

9. Vaccine Adjuvants Market, by Application

• 9.1. Introduction
• 9.2. Human
• 9.3. Veterinary

10. Americas Vaccine Adjuvants Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Vaccine Adjuvants Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Vaccine Adjuvants Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
  • 13.3.2. Croda Partners on Vaccine Adjuvants
  • 13.3.3. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agenus Inc.
• 2. Aphios Corporation
• 3. Bioveta, A.S.
• 4. Croda International PLC
• 5. CSL Limited
• 6. Dynavax Technologies Corporation
• 7. GlaxoSmithKline PLC
• 8. Hayashibara Co., Ltd. by NAGASE & CO., LTD.
• 9. InvivoGen
• 10. Merck KGaA
• 11. Novavax, Inc.
• 12. OZ Biosciences SAS
• 13. Pacific GeneTech Limited
• 14. Takeda Pharmaceutical Company Limited
• 15. Thermo Fisher Scientific Inc.